Abivax SA (NASDAQ: ABVX) — A De-Risked Oral IBD Asset Priced for a Clean Label It Doesn’t Yet Have

**Date: 2026-07-03 · Sector: Health Care — Biotechnology (clinical-stage) Instrument: Nasdaq Global Market ADSs (1 ADS = 1 ordinary share), primary listing Euronext Paris (ABVX) · CIK 0001956827 · CUSIP 00370M103 · ISIN US00370M1036

⚡ Claude’s Take

This block is the author’s own, independent subjective opinion. It is general information, not investment advice, and is not any firm’s investment recommendation. The analysis that follows deliberately carries no recommendation and no price target — this block is the single exception.

Verdict: HOLD / not-a-short — a genuinely de-risked, best-in-class-efficacy oral for ulcerative colitis, priced (~$12.5B market cap / ~$11B EV at $144.65) for a clean regulatory label and a takeout premium it has not yet earned. Accumulate only into safety-driven fear — the sub-$85–100 zone that the June-2 malignancy panic briefly opened — not at an all-time high struck the day after an $800M raise.

Abivax has done the hard part. Obefazimod’s Phase 3 ABTECT maintenance data (~51% Week-44 clinical remission vs 10.4% placebo, ~48% corticosteroid-free) is top-tier and comparable to the best oral in the class (upadacitinib) and the best IL-23 (mirikizumab) — delivered in a pill, via a novel miR-124 mechanism that carries none of the JAK class’s mechanistic malignancy baggage. If that were the whole story, the stock would be cheap. It is not the whole story. The entire premium over a “me-too oral” rests on obefazimod being an oral with biologic-grade durability and a clean safety label — and on June 2, 2026 the market discovered that the 50 mg arm carried a cluster of malignancies (prostate, breast, colonic dysplasia, plus non-melanoma skin cancers), enough to erase 44% of the equity in a single session before a partial recovery. Management’s own exposure-adjusted analysis shows the integrated-program rate (0.35/100 patient-years) sits inside the published UC background range — but the Phase-3-maintenance-only 50 mg rate (0.91) sits above it. That is not a settled question; it is the exact question the FDA will adjudicate at the late-Q4-2026 NDA. The market is pricing the favorable answer.

The framing is a coiled clinical binary, de-risked on efficacy but not on label — >99% of the stock’s return variance is drug-specific, not factor- or market-driven (a factor model explains under 1% of its return variance). At ~$11B EV the tape embeds ~$3.5–5.5B of fully-credited peak sales plus the ever-present ~$20B+ takeout call option (Lilly/AZ rumored) — i.e., the bull case, paid up front, with the safety asterisk treated as noise. I don’t short it (de-risked efficacy + a live takeout bid is a widow-maker short), and I don’t chase it here. Conviction: medium. The single fact that flips me bullish: a clean or near-clean FDA label (no malignancy boxed/black-box warning) enabling 1st-line oral positioning. The single fact that flips me bearish: an FDA malignancy warning, a CRL, or Crohn’s (ENHANCE-CD) failure that collapses the franchise to a single restricted-label indication. Catchy version: the efficacy is approved in my head; the label is still on trial.

📈 Stock Price Action — Five-Year Event Map

A note on window: Abivax’s U.S.-tradable Nasdaq ADSs (ABVX) only began trading on 2023-10-20, and the price series available here starts 2025-07-23 — so this “five-year” map is really ~11.5 months of Nasdaq history. The longer arc lives on the primary Euronext Paris line (ABVX, listed 2015), where the stock re-rated roughly 20-fold over the past year (52-week range ~€6.55 to €132.00; all-time low €3.85 in 2016) — a sub-€10 microcap detonated by positive Phase 3 induction data in 2025.

On the Nasdaq line, ABVX round-tripped violently: from a ~$62.50 debut low (2025-07-23) to a $148.83 high (2025-12-24), then a −44% single-day crash on the June-2026 safety signal to $72.50, and a sharp recovery to $144.65 (2026-07-02) — leaving the stock just −2.8% off its all-time high after a year in which almost the entire move concentrated in a handful of binary catalyst days. 52-week range ~$62.50–$148.83; current $144.65; 90-day average volume ~1.6M ADS (catalyst days 4–16M).

Cycle narrative. (1) The Nasdaq series opens at a ~$63 low the same month as a $747.5M raise that extended runway toward the NDA — the U.S. line begins already elevated by earlier positive induction data (price/offering = Fact; driver = Interp). (2) Through H2-2025 the ADS more than doubles to a $148.83 high on continued induction-data confidence and mounting M&A speculation — a grind, not a gap. (3) January 2026 gives back to ~$111 amid takeover rumors and profit-taking. (4) Feb–May drifts up to ~$133 on low volume into the pivotal maintenance readout. (5) On June 2 the stock craters −44% (volume ~16M, ~10× normal): maintenance efficacy was strong but a 50 mg malignancy signal dominated the tape. (6) June 3–4 rebounds +45% as management/KOL context reassured. (7) June 29–30 gaps +39% on positive Maintenance Part 2 plus a strengthened safety database. (8) July 2 an $800M ADS offering is absorbed without discount and the stock closes $144.65, ~−2.8% off its record. The price move in each row is a Fact; the attributed cause is Interpretation.

1. Executive Summary

Abivax is a 69-employee, Paris-headquartered, Nasdaq- and Euronext-listed clinical-stage biotechnology company that is, for all practical purposes, a single-asset company. That asset is obefazimod (formerly ABX464), an oral, once-daily, first-in-class small molecule that enhances expression of a single anti-inflammatory microRNA (miR-124) and is in Phase 3 for moderate-to-severely-active ulcerative colitis (UC) (the ABTECT program) and Phase 2 for Crohn’s disease (ENHANCE-CD). There is no marketed product, essentially no revenue, and no commercial infrastructure. The company funds itself entirely by issuing equity; it intends to file a U.S. NDA in late Q4 2026, implying a potential first launch around 2027–2028.

The investment case is not a business — it is a binary de-risking event on a finite patent clock. In 2025–2026 obefazimod cleared the two highest bars in drug development: positive Phase 3 induction (Week 8) and, decisively, positive Phase 3 maintenance (Week 44). The maintenance efficacy — ~51% clinical remission at 50 mg vs 10.4% placebo (Δ~40pp), ~48% endoscopic remission, ~48% corticosteroid-free remission, ~66% sustained remission — is best-in-class-comparable for advanced UC therapy and, uniquely, is delivered orally through a mechanism with no theoretical malignancy link (unlike the JAK class). On efficacy alone, obefazimod ranks with the best drugs in the category.

The catch, and the entire debate, is safety. The June-2026 maintenance readout revealed a cluster of malignancies confined to the 50 mg arm — one prostate, one breast, one colonic dysplasia, plus four non-melanoma skin cancers — which triggered a −44% one-day crash. Management’s exposure-adjusted analysis argues the integrated all-active rate (0.35/100 patient-years) is within the published UC background range (0.30–0.70); the bear notes the Phase-3-maintenance-only 50 mg rate (0.91) exceeds it. Whether the FDA imposes a malignancy warning (as it did on the entire JAK class) is the swing factor for the drug’s commercial ceiling, and it will be adjudicated at the NDA.

Financially, the company is well-capitalized after two large 2025–2026 raises. Pro-forma for the July 2026 $800M offering (6.4M ADSs at $125; ~$762M net), Abivax holds ~$1.2–1.3B of cash against ~€200M/year-and-rising cash burn (Q1’26 operating burn ~€50.5M), giving runway “into Q2 2029” — through approval, though likely not through a full independent launch. Share count has grown from ~19M (2022) to ~86.1M pro-forma basic (~95M fully diluted) — a company that has funded a decade of R&D by selling roughly 4.5× its 2022 share base. The most recent raises were struck into post-data strength, which is capital-allocation-competent; the cumulative dilution is nonetheless the defining feature of the equity.

At ~$144.65, the ~$11B enterprise value embeds roughly $3.5–5.5B of fully-credited peak sales — the base-to-bull scenario — with FDA approval largely assumed and the malignancy label assumed benign, atop a standing takeout option (rumored suitors Eli Lilly and AstraZeneca; deal-value speculation up to ~$23B). This is a de-risked asset priced for its best-case regulatory outcome. There is no durable competitive moat in the Greenwald sense: the “moat” is a bundle of finite, expiring patents (composition-of-matter to 2030, method-of-use to 2035, blended to ~2039 with extensions) plus first-in-class novelty, monetized either through a self-commercialized launch or, far more likely, an acquisition. No recommendation and no price target appear below; the memo discusses valuation only as embedded expectations and scenarios.

2. Business Overview

What the company is. Abivax S.A., founded 2013 and headquartered in Paris with R&D in Montpellier and a U.S. office in Waltham, Massachusetts, is a clinical-stage biopharmaceutical company developing therapeutics that harness the body’s natural regulatory mechanisms to control chronic inflammation. It IPO’d on Nasdaq in October 2023 (having listed on Euronext Paris in 2015) and employs ~69 people. It is a foreign private issuer, filing Form 20-F annually and Form 6-K for interim disclosures rather than 10-K/10-Q; it reports in euros (functional currency) while its ADSs trade in U.S. dollars.

The single asset: obefazimod (ABX464). Obefazimod is an oral, once-daily small molecule (8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine) that binds the cap-binding complex/ARS2 and redirects RNA splicing to selectively up-regulate miR-124, a single anti-inflammatory microRNA. Enhanced miR-124 down-regulates multiple pro-inflammatory cytokines (IL-6, IL-17, TNF-α, CCL2) and dampens immune-cell activation. It is described as a first-in-class “miR-124 enhancer.” (FACT — source: PMC10132720, 2023; Abivax science page, accessed 2026-07-03.) This mechanism is genuinely novel: no approved IBD drug works via microRNA/splicing modulation, and — critically — it is not the JAK mechanism, so the theoretical immune-surveillance/malignancy link that saddles the JAK class is mechanistically absent (INTERPRETATION).

The pipeline is obefazimod, twice. Two indications carry essentially all the value:

• Ulcerative colitis (ABTECT) — the lead Phase 3 program: two induction trials (ABTECT-1, ABTECT-2) plus a re-randomized-withdrawal maintenance trial (Part 1) and a supplemental maintenance trial for non-responders/relapsers (Part 2). Induction and maintenance data both read out positive (2025 and June 2026 respectively). NDA planned late Q4 2026.
• Crohn’s disease (ENHANCE-CD) — a Phase 2b in moderate-to-severe Crohn’s (NCT06456593), first patient dosed Q4 2024, once-daily obefazimod, placebo-controlled. Crohn’s is a market roughly as large as UC; a positive readout would approximately double the addressable franchise. (Readout timing is contested — company framing suggests 2H2026, independent trial trackers cite a mid-2027 12-week induction readout; OPEN QUESTION.)

Legacy earlier-stage assets (ABX196 in hepatocellular carcinoma; historical HIV/RSV/influenza work) carry negligible value and are not the reason to own the stock.

How it makes money: it doesn’t, yet. Abivax is pre-revenue. Reported “revenue” is immaterial (grant/other income). All cash comes from equity issuance and, to a lesser extent, the French research tax credit (Crédit d’Impôt Recherche). The business model, if approval is achieved, is a classic specialty-pharma one: a high-priced (~$30–70k/year gross), chronically-dosed oral for a large, growing autoimmune market — sold either by a salesforce Abivax would have to build from scratch, or (the market’s base case) by an acquirer. Revenue is entirely a future, probability-weighted event.

Verdict. A clean, understandable single-asset story: one oral drug, one novel mechanism, two large IBD indications, one imminent regulatory catalyst. The simplicity is the point — obefazimod’s Phase 3 data is the company. Everything that follows is about how good that drug is, how safe, how protected, and how much of its success is already in the price.

3. Industry Dynamics

The end-market is structurally attractive — and intensely competitive. Moderate-to-severe ulcerative colitis is a large, chronic, high-priced, growing market with rising advanced-therapy penetration. UC prevalence is ~1.0–1.25M in the U.S. and ~1M+ across the EU5; roughly 30–40% of diagnosed patients are moderate-to-severe (~350–600k U.S.), of whom an advanced-therapy-treated pool of ~250–400k and growing receive biologics/JAKs/S1P modulators. (FACT/ASSUMPTION — aggregated UC epidemiology, GMInsights/DelveInsight, accessed 2026-07-03.) The global UC drug market is ~$8–9B (2024), projected to ~$15.5–16.5B by 2033–34 (~6% CAGR); the broader IBD (UC+CD) market is ~$20.7B (2023) heading to ~$27.7B by 2030. (FACT — GMInsights; Grand View; iHealthcareAnalyst.) Annual U.S. list prices anchor the economics: upadacitinib ~$72k, risankizumab ~$150–190k, vedolizumab high-five-figures; net realized prices run ~45–55% of list after rebates.

But the competitive intensity is severe and rising — the defining structural fact. The advanced-UC shelf already holds:

• Anti-TNF (adalimumab/Humira, infliximab) — legacy 1st-line biologics, now heavily biosimilar-eroded (Week-8 remission ~16–18%).
• Anti-integrin — vedolizumab (Entyvio, Takeda): gut-selective, exceptionally clean safety, slower onset (GEMINI-1 Week-52 remission ~42–45% vs ~16% placebo).
• IL-23p19 inhibitors — mirikizumab (Omvoh, Lilly), risankizumab (Skyrizi, AbbVie), guselkumab (Tremfya, J&J): strong efficacy, near-impeccable safety, injectable.
• JAK inhibitors (oral) — tofacitinib (Xeljanz), upadacitinib (Rinvoq): the fastest, deepest induction in class, but carrying an FDA boxed warning for serious infection, mortality, malignancy, MACE and thrombosis that legally confines them to post-TNF-failure 2nd-line+.
• S1P modulators (oral) — etrasimod (Velsipity, Pfizer), ozanimod (Zeposia, BMS): oral, moderate efficacy, with cardiac/bradycardia and macular-edema monitoring.
• Anti-TL1A (emerging) — tulisokibart (Merck/Prometheus; Phase 3 ATLAS-UC positive 2026) and duvakitug (Sanofi/Teva): the most-hyped next wave, precision biologics with potentially best-in-class efficacy and clean safety.

Capital-cycle read (Marathon lens). UC is a textbook case of “high returns attract capital.” The commercial success of Humira, Entyvio, Skyrizi and Rinvoq has drawn a flood of development capital into IBD — three IL-23s, two JAKs, two S1Ps, and now an incoming TL1A wave, all competing for the same ~$15B pool. This is capital-cycle deterioration in the making: more mechanisms, more agents, intensifying payer step-therapy and rebate pressure, and — eventually — margin/pricing compression as the shelf crowds. A new entrant must win share by label and detailing, not by any structural entry barrier; there is no supply constraint and no scarcity of effective options.

Verdict: structurally good market, structurally difficult competitive position. The disease pool is large, chronic, growing and well-reimbursed — a good place to sell a drug. But it is one of the most crowded therapeutic categories in all of pharma, getting more crowded, with several competitors that are both highly effective and impeccably safe. Obefazimod’s only structural differentiation is being an oral with (contingent) clean safety; strip the safety differentiation and it is one more entrant in a field of ten. The industry rewards the asset, but offers it no protection.

4. Competitive Position

The efficacy case is strong — genuinely best-in-class-comparable on maintenance. Judged head-to-head against the class (acknowledging trial-design differences), obefazimod’s positioning is:

(FACT — obefazimod: Abivax PRs/6-Ks 2025-07 & 2026-06; comparators: RINVOQ U-ACHIEVE/U-ACCOMPLISH, Omvoh LUCENT, Velsipity ELEVATE, GEMINI-1.)

The read is precise: obefazimod’s maintenance efficacy (~51% Week-44 remission among induction responders, the widest placebo-adjusted delta in class) is top-tier — level with the best oral (upadacitinib 30 mg) and the best IL-23 (mirikizumab), and it is delivered in a pill. Its induction is the relative weak spot: ~16pp placebo-adjusted at Week 8 is in line with IL-23s and S1Ps but below the JAKs and the emerging TL1As. Obefazimod is a slower-onset, high-durability oral — the pitch is durable remission, not rapid rescue of a flaring patient, and gastroenterologists do value fast induction. Net: “biologic-like efficacy in an oral” is supported on maintenance and roughly true (mid-pack) on induction.

The whole premium is a safety-label bet — and the label is contested. The commercial thesis is that obefazimod is an oral with JAK-like maintenance efficacy but without the JAK boxed warning, enabling earlier-line/1st-line oral use where JAKs are confined to 2nd-line+. The June-2026 malignancy signal — three non-NMSC malignancies (prostate, breast, colonic dysplasia) plus four NMSC, all in the 50 mg arm, mean age 62 vs trial 42, all “considered unrelated,” across 1,704 patient-years — directly threatens the differentiator. If the FDA imposes a malignancy warning or a restrictive 2nd-line label, obefazimod collapses into the same regulatory box as the JAKs and loses the oral-1st-line edge that justifies the premium and the takeout math.

The exposure-adjusted data cuts both ways, and precisely along the bull/bear line (FACT — 424B5 2026-07-02, malignancies ex-NMSC, per 100 patient-years):

The bull reads the integrated all-active rate (0.35) as comfortably within UC background, the 25 mg arm as clean (0.00), the small absolute counts in older patients, and the “unrelated” adjudication. The bear reads the 50 mg Phase-3-maintenance rate (0.91) — above the upper bound, in the exact dose and duration of intended commercial use — as a dose-dependent malignancy signal that a cautious FDA (post-JAK-class experience) may not wave through. This is not a resolved question; it is the single most important unresolved fact in the entire thesis (INTERPRETATION).

Moat verdict — be direct: there is no durable competitive advantage. A single-asset clinical-stage biotech has no Greenwald moat in the durable sense — no supply/cost advantage, no customer captivity, no economies of scale, no network effect. The “moat” is a bundle of finite, legally-expiring protections (FACT — 20-F FY2025 patent schedule):

• Composition-of-matter patents (US 10,017,498; 10,975,063) expire 2030 — alarmingly close, and the 20-F explicitly flags this as “a risk to successful commercialization.”
• Method-of-use patents (treating inflammatory disease incl. UC/CD) expire 2035.
• Synthesis/polymorph patents expire 2037; newer UC-specific filings, if granted, could extend protection into the early 2040s.
• The company “expects to seek” Hatch-Waxman patent-term extension (up to 5 years) and ~5-year NCE regulatory data exclusivity from approval, representing blended protection “to ~2039.”

The first-in-class mechanism is a de-risking narrative, not a barrier — fast-followers can pursue other oral IBD mechanisms (oral TL1A, next-gen S1P, other splicing/miR approaches), and at loss-of-exclusivity a small-molecule oral is fully generic-vulnerable. This is a single de-risking binary on a ~10–13-year effective patent runway, not a compounding franchise. The value is the approval and the acquisition it invites, monetized against a patent clock that starts ticking loudly by the mid-2030s. Verdict: no durable advantage beyond patents + regulatory exclusivity + first-mover — an asset, not a moat.

5. Growth History and Forward Opportunities

For a pre-revenue biotech, “growth” is not revenue growth — it is clinical de-risking and label/indication expansion. On that axis the trajectory has been strongly positive:

• Phase 2b (2021): obefazimod delivered proof-of-concept in UC, establishing the miR-124 mechanism clinically and justifying the Phase 3 investment.
• Phase 3 induction (2025): both ABTECT-1 and ABTECT-2 hit the FDA primary endpoint at Week 8 (50 mg pooled Δ16.4pp placebo-adjusted clinical remission; 25 mg Δ21.4pp in ABTECT-1), in a refractory population (~47% prior advanced-therapy failure, ~21% prior JAK failure). This was the first pivotal de-risking event and drove the initial re-rating.
• Phase 3 maintenance (June 2026): the decisive readout — Week-44 clinical remission 51.3% (50 mg)/50.8% (25 mg) vs 10.4% placebo, with endoscopic remission ~48%, corticosteroid-free remission ~48%, and sustained remission ~66%, plus Part 2 confirming benefit in induction non-responders (37.2% remission at 50 mg) and relapsers (45.0%). This is the data package that supports the NDA.

Forward opportunities. (1) NDA and approval — the near-term inflection: filing late Q4 2026, potential U.S. approval and launch ~2027–2028; EU filing (EMA) to follow. (2) Crohn’s disease (ENHANCE-CD) — the single largest source of upside optionality: a market roughly as large as UC, with a Phase 2b readout in 2H2026–mid-2027 (timing contested). A positive CD signal would approximately double the addressable franchise and materially raise any takeout price. (3) Line-of-therapy expansion within UC — if the label is clean, movement from 2nd-line into 1st-line oral use unlocks the largest, least-penetrated patient pool. (4) Geographic and label breadth — ex-US markets, and potentially other inflammatory indications the mechanism could address.

Quality of the growth. High-quality in the sense that it is pivotal-data-driven and franchise-defining, not incremental. But it is binary and lumpy, not compounding — each step is an all-or-nothing catalyst, and the same maintenance readout that delivered best-in-class efficacy also delivered the malignancy signal. The growth is real, it is large, and it is entirely contingent on the FDA and on the CD readout. Verdict: high-quality but binary de-risking growth — the value has been created by the data and will be realized (or destroyed) by the label and the CD readout.

6. Financial Quality

The standard financial-quality lens (ROIC, ROE, margins, operating leverage, FCF conversion) does not apply to a pre-revenue biotech and would be misleading — there are no revenues, no margins, and deeply negative returns on capital by construction. The correct lens is burn, runway, balance-sheet strength, and the quality/cost of financing.

Cash burn is large and accelerating with the program. Operating expense has scaled with the Phase 3 program: R&D €103.2M (2023) → €146.5M (2024) → €177.8M (2025); total operating loss €127.4M (2023) → €173.0M (2024) → €246.1M (2025). FY2025 net loss was €336.1M, but that figure is inflated by ~€84M of non-operating charges — principally non-cash share-based comp and fair-value remeasurement/interest on the (now converted) Heights convertible and Kreos venture debt — so net loss materially overstates cash burn; the operating cash burn is the cleaner run-rate proxy (INTERPRETATION). Operating cash burn was ~€97M (2023) → ~€154M (2024) → ~€161M (2025), and is now higher: Q1’26 operating burn was ~€50.5M (R&D €49.5M, +26% YoY) — i.e., ~€200M+ annualized and rising into Phase 3 completion, NDA, and a U.S. pre-commercial build. (The quarterly cash-plus-STI balance fell only ~€39M in Q1’26 (€530.4M → €491.6M) — the gap to the €50.5M operating burn is working-capital timing and interest income, not a large recurring offset.) Notably, the French Crédit d’Impôt Recherche is immaterial here (only ~€3.1M in FY2025 vs €178M of R&D — most trials run ex-France, which caps the credit), so it is not the burn cushion it is for many French biotechs; do not model it as one. (FACT — ROIC/20-F income statements & cash-flow statements FY2022–Q1’26.)

The balance sheet is strong post-recapitalization. The trajectory is stark: Q2’25 showed negative total equity of −€48.3M with ~€85M of gross borrowings and only €60.9M of cash — a genuinely stressed balance sheet — before the July 2025 raise transformed it. By Q1’26 (Mar 31): cash + short-term investments €491.6M, total equity €429.6M, net cash ~€477M, and gross debt reduced to ~€1.4M of capital leases (the Kreos/Heights instruments repaid or converted to equity). Pro-forma for the July 2026 $800M offering (~$762M net, ~€700M), cash rises to roughly €1.1B+ (~$1.2–1.3B) against negligible debt, funding operations “into Q2 2029.”

Runway credibility. ~$1.2–1.3B (~€1.1B) against a current ~€200M/year-and-rising burn backs the stated runway “into Q2 2029” — but burn will ramp materially through NDA review, Crohn’s Phase 3, and a potential U.S. commercial build (salesforce, launch inventory, medical affairs), so the guidance implies an average burn ramping toward ~€300M+/year. There is no near-term financing cliff; the July 2026 raise removed refinancing risk through the entire NDA/approval window. But a self-funded commercial launch would very likely require one more raise — the runway funds through approval, not comfortably through a full independent launch, which is part of why a takeout (or partnership) is the market’s base case. (INTERPRETATION.)

Quality-of-earnings flags (biotech-specific). (1) Net loss is not a clean burn proxy — strip the non-cash convert remeasurement/interest. (2) The CIR tax credit is a real, recurring cash inflow that flatters net burn and depends on continued French R&D activity — model it explicitly. (3) There is goodwill/intangibles of ~€44M (the ABX464 CGU) carried at cost and not amortized; it is subject to impairment if the program fails — a fair carrying value only while the asset is live. (4) Functional-currency EUR vs USD-denominated ADSs introduces FX translation noise in reported figures. Verdict: economics are deeply negative by design (as for any clinical biotech), but the balance sheet is strong, the burn is well-understood and financed through the key catalyst, and the accounting is conservative — the financial risk is dilution and time, not insolvency.

7. Capital Allocation

Capital allocation here means one thing: how, when, and at what price the company sells equity to fund the program — and it has done so competently, if inevitably dilutively. Abivax has never generated cash from operations; it has funded a decade of R&D entirely through equity and debt issuance. Share count has grown roughly as follows (weighted-average diluted / period-end): ~19.1M (2022) → ~43.1M (2023, IPO year) → ~63.3M (2024) → ~69.5M (2025 avg) → 79.3M (Q1’26) → 86.1M pro-forma (July 2026). That is ~4.5× the 2022 base and ~2.0× since the 2023 Nasdaq IPO. Serial, structural dilution is the single defining feature of this equity — anyone underwriting the upside must underwrite the shares that will fund the path to it, including a likely future pre-commercial raise if the company stays independent.

But the timing has been shareholder-competent — raises struck at strictly ascending, into-strength prices. The financing sequence runs €6.50 (early private rounds) → €10.99 (2023 Nasdaq IPO) → ~$64/ADS ($747.5M, July 2025, post-induction) → $125/ADS ($800M, July 2026, upsized and oversubscribed, post-maintenance) — each raise at a higher price than the last, into a data-driven re-rating rather than out of desperation. The July 2026 offering (6.4M ADSs at $125, ~$762M net) was priced the day after the +38% Part-2 pop, at only a ~6% discount to the prior close, and the stock closed higher the next session ($144.65) — raising $800M at a ~$11B valuation near an all-time high minimizes dilution per dollar, the opposite of the death-spiral financing that destroys clinical biotechs. (FACT — 424B5 2026-07-02; 5-year price history.) The company also repaired and cleaned up its capital structure: the Kreos venture debt and Heights Capital convertible (peak ~€114M gross debt; equity went negative −€48M in Q2’25) were fully converted/prepaid by December 2025, and royalty certificates were repurchased (~$90M, May 2026) — leaving a nearly debt-free balance sheet with +~€430M equity by Q1’26 and removing a source of dilutive/coercive financing overhang.

The dilution is nonetheless real and includes a large option overhang. Beyond the ~86.1M pro-forma basic ADSs, there is ~8.86M of options/BSA/BSPCE, taking the fully-diluted count to ~95M — a further ~10% of latent dilution (much of it now in-the-money after the run) that any valuation must carry.

The dual signal of the July 2026 raise. Raising $800M into post-data strength both (a) funds an independent path — reducing pressure to sell the company cheaply — and (b) is not what a company on the cusp of a signed takeout typically needs. It buys negotiating leverage. CEO Marc de Garidel publicly stated (March 2026) he was “in no rush” for a deal and expected the June maintenance data to “secure better terms,” and Abivax explicitly denied reports that it had given AstraZeneca exclusive data-room access. (FACT — CNBC 2026-01/03; company statements.) The read: management is playing for a higher takeout price (or a well-funded independent launch), not a fire sale.

Incentives and insiders. Management compensation is heavily equity-linked (options/BSA/BSPCE) atop modest cash (CEO Marc de Garidel ~€1.05M cash + SBC), aligning management with the share price and the binary outcome — appropriate, though also a source of ongoing dilution. Insider ownership is low (~1.4%), and as a foreign private issuer Abivax is exempt from Section 16 Form 4/144 reporting, so there is no clean domestic insider-transaction signal to read (a genuine information gap vs a U.S. filer). Institutional ownership is concentrated among specialist healthcare/biotech crossover funds: Invus ~8.5%, TCG Crossover / Chen Yu ~9.1%, Darwin ~5.4%, with Sofinnova, Deep Track, Venrock and Truffle Capital now diluted below 5% and trimming into strength. There is no evidence of value-destructive M&A, empire-building, or related-party abuse — the capital has gone into the drug. Verdict: capital allocation has been competent within the only game available — fund the asset, time the raises into strength, clean up the debt, preserve optionality for a premium exit. The unavoidable cost is heavy cumulative dilution; the avoidable mistakes (bad-price raises, coercive converts left outstanding) have largely been avoided.

8. Changes and Headwinds — Last Two Years

The trailing ~24 months contain essentially the entire investment history of the equity:

• Oct 2023: Nasdaq IPO (dual-listing the Euronext name), broadening the capital base for the Phase 3 push.
• 2024: ABTECT Phase 3 UC program fully enrolled (>600 sites, 36 countries); ENHANCE-CD Crohn’s Phase 2b initiated (first patient Q4 2024).
• 2025 (H1–H2): Positive Phase 3 induction data (both ABTECT trials hit Week-8 primary endpoint); the stock re-rated ~20-fold on the Paris line over the year and became Europe’s best-performing large biotech. A stressed mid-2025 balance sheet (negative equity, Heights convert) was repaired by the ~$747.5M July 2025 raise, extending runway toward the NDA.
• June 1–2, 2026: Positive Phase 3 maintenance data (Part 1) — best-in-class efficacy — but the 50 mg malignancy signal drove a −44% single-day crash, the defining risk event. A +45% two-day rebound followed on safety reassurance.
• June 29–30, 2026: Maintenance Part 2 positive (non-responders/relapsers) and a strengthened safety database (1,704 patient-years integrated exposure) → +38%.
• June 30–July 2, 2026: The $800M ADS offering (6.4M @ $125), priced into the spike; runway extended “into Q2 2029.”
• Throughout 2025–2026: Persistent M&A speculation — rumored suitors Eli Lilly and AstraZeneca, deal-value chatter up to ~$23B — with the company denying AZ data-room reports and signaling patience.

Headwinds/overhangs going forward: (1) the FDA malignancy adjudication at the late-Q4-2026 NDA — the dominant swing factor; (2) Crohn’s readout risk (ENHANCE-CD) — timing contested, outcome unknown; (3) competitive escalation — the TL1A wave (tulisokibart Phase-3-positive, duvakitug) and entrenched clean-safety IL-23s crowding the shelf obefazimod would launch into; (4) commercial-build execution risk if it stays independent (a first-launch biotech building a U.S. GI salesforce); (5) further dilution; (6) patent-cliff proximity (composition-of-matter 2030). Verdict: the last two years created the value (two positive pivotal readouts, a repaired balance sheet, standing takeout interest) and simultaneously exposed the central risk (the malignancy signal). The changes strengthen the thesis on efficacy and financing, and sharpen — do not resolve — the safety and valuation risk.

9. Risk Analysis (Risk Matrix)

The dominant risks are regulatory (malignancy label, #1) and valuation (#9), both High-impact and non-trivially likely, compounded by single-asset concentration (#10). The mitigant against a catastrophic total loss is the strength of the efficacy data (which makes outright non-approval, #2, less likely) and the standing takeout interest (#8) — but neither is guaranteed, and #1 can impair the thesis without any of the tail risks firing.

10. Valuation Discussion (Embedded Expectations)

The correct valuation frame is a probability-weighted, patent-cliffed peak-sales model, read backward from the price — not multiples of (non-existent) earnings. Conventional multiples are meaningless here: P/E is null (deeply negative EPS, −€4.83 FY2025), P/S is absurd (near-zero revenue; its P/S percentile of 99.9 is a divide-by-~zero artifact, not a signal), and P/B (~17× book) merely reflects that book value is mostly the cash raised. Own-history valuation percentiles (composite 99th) are un-interpretable for a pre-revenue biotech and should be ignored (INTERPRETATION).

What the price embeds. At $144.65, pro-forma ~86.1M basic shares → ~$12.45B market cap; less ~$1.2–1.3B pro-forma net cash → ~$11.2B enterprise value (at the $125 offer price, ~$10.8B cap / ~$9.5B EV; on the ~95M fully-diluted count the cap is ~$13.7B). Against the peak-sales scenarios developed in the industry and competitive sections above:

De-risked (post-approval) specialty-pharma assets typically trade around ~2–4× peak sales; a pre-approval asset should trade at a discount to that for regulatory and launch risk. At ~$11.2B EV the market is capitalizing roughly $3.5–5.5B of peak sales at a near-approved multiple — i.e., the base-to-bull outcome, with FDA approval largely assumed and the malignancy label assumed benign and substantial Crohn’s/first-line optionality credited. Put the other way: a disciplined risk-adjusted valuation on the base case (~$2.5–3B peak, ~60–75% probability-of-approval-and-launch given strong Phase 3 but a live safety question, discounted for time and dilution to ~2027–2032 realization) lands closer to ~$6–9B EV — meaningfully below the current ~$11.2B. The gap between that and the tape is the bull-case + takeout premium the market is paying up front.

The takeout option is doing real work in the price. Rumored deal-value speculation up to ~$23B (~$260+/share) means the acquisition call is a live, valuable component of the current quote — arguably the reason the stock trades near an all-time high despite an unresolved safety question. An acquirer (Lilly, AZ) underwriting ~$4–5B peak at ~4–5× would justify a ~$20B+ price if the label is clean; the same acquirer facing a malignancy-warned label would bid far less or walk. So even the takeout math is a levered bet on the same safety adjudication.

Embedded-expectations summary — what the market is underwriting correctly vs. aggressively. Correctly: that the efficacy is best-in-class-comparable and the drug is very likely approvable in some form; that the balance sheet is funded through the catalyst; that takeout interest is real. Aggressively: that the FDA malignancy adjudication lands benign (no label restriction), that obefazimod captures broad 1st-line oral share against clean-safety incumbents and an incoming TL1A wave, that Crohn’s adds optionality, and that a premium takeout closes — with little margin of safety for any of these going the other way, at a price set the day after an $800M raise, near the all-time high. No price target and no recommendation — the point is that the current EV requires the good outcome on nearly every contested variable simultaneously.

11. Variant Perception

Consensus. The bull consensus — reflected in the price near its all-time high, the sell-side’s largely-retained positive ratings through the June whipsaw, and the persistent M&A chatter — is that obefazimod is a de-risked, best-in-class oral for UC whose malignancy signal is background noise (older patients, small counts, no mechanistic link, integrated rate within UC range), that FDA approval with a workable label is highly likely, that Crohn’s adds a second large indication, and that a $20B+ takeout by Lilly or AZ is the probable endgame. On this view the stock is a ~$12B company on its way to ~$20B+.

The strongest bull case. The efficacy is not in dispute and it is genuinely excellent — ~51% Week-44 remission, corticosteroid-free, durable, oral. The mechanism is novel and not JAK, so there is no biological reason to expect a JAK-like malignancy profile; the June signal is plausibly a small-number artifact in an older sub-population, and the 25 mg arm (the likely commercial dose emphasis) was clean (0.00). An oral that matches injectable biologics on durable remission, with a manageable label, is a multi-billion-dollar 1st-line franchise and a must-own asset for any large IBD player — the takeout writes itself.

The strongest bear case. The premium is entirely a clean-label bet, and the label is genuinely uncertain: the 50 mg Phase-3-maintenance malignancy rate (0.91/100PY) sits above the UC background range in the exact dose/duration of intended use, and a post-JAK-experience FDA has shown it will box an entire oral class on a malignancy signal. A malignancy warning would confine obefazimod to 2nd-line, collapse it into the JAK box, and slash both peak sales and any takeout price — with the stock at ~$11B EV pricing the opposite. Even absent a warning, obefazimod launches into the most crowded category in pharma, against clean-safety IL-23s and an incoming best-in-class TL1A wave, as a slower-onset oral, with a finite patent runway (CoM 2030) and no compounding moat — while diluting shareholders ~4.5× since 2022. The price bakes in the bull outcome on every contested variable at once, with no cushion.

The 3–5 assumptions that matter most, and what would falsify each:

1. The FDA label is clean (no malignancy restriction). Falsified by: a malignancy warning/boxed warning or a 2nd-line-restricted label at approval.
2. Approval happens on the Q4-2026 NDA timeline. Falsified by: a CRL, a REMS beyond routine, or a material delay.
3. Obefazimod wins broad (incl. 1st-line) oral share. Falsified by: payers/GIs defaulting to clean IL-23s/TL1A; obefazimod stuck in post-biologic 2nd-line.
4. Crohn’s adds a second large indication. Falsified by: an ENHANCE-CD miss or a much later/weaker readout than framed.
5. A premium takeout closes (or an independent launch succeeds). Falsified by: M&A interest fading with no signed deal and an underwhelming self-launch.

Positioning read (from the tape). ABVX is a coiled clinical binary, not a crowded momentum trade nor a cleanly de-risked re-rating. a quantitative factor model can barely fit it (R²≈0.7%; the model even mis-tags the sector), because >99% of its return variance is obefazimod-specific — efficacy, the malignancy overhang, and takeover optionality — not factor or market beta. The June-2 −44% reaction proves the market will punish safety asymmetrically into the NDA; sitting −2.8% off its all-time high the day after an $800M raise, the stock prices a favorable regulatory path with essentially no cushion. The variant perception worth holding: the efficacy is de-risked and the market is right about that; the label is not de-risked and the market is pricing it as if it were. The mispricing, if any, is not in the drug — it is in the certainty the price assigns to a still-open FDA question.

12. Fact vs. Interpretation Table

13. Open Questions

1. What label will the FDA grant? Specifically: any malignancy warning/boxed warning, and any line-of-therapy restriction? This single question dominates the thesis.
2. Is the malignancy signal real or noise? Will it grow with longer exposure/open-label extension, and is 25 mg (clean to date) sufficient efficacy to make it the emphasized dose?
3. When does Crohn’s (ENHANCE-CD) read out, and does it work? 2H2026 (company framing) vs mid-2027 (trackers) — and UC efficacy does not guarantee CD efficacy.
4. Independent launch or takeout — and at what price? Does a Lilly/AZ deal actually close, and is it struck before or after the label is known (the label swings the price enormously)?
5. Effective patent life post-PTE. Does composition-of-matter (2030) get extended, and do the UC-specific filings grant and survive challenge, to reach the claimed ~2039?
6. Commercial-share realism. In a shelf with three clean IL-23s and an incoming TL1A wave, what 1st-vs-2nd-line share can a slower-onset oral actually capture?
7. Next financing. If independent, how large is the pre-commercial raise, and at what dilution?

14. What Must Be True

For the bull case (current price is justified or cheap):

• The FDA approves obefazimod on the Q4-2026 NDA with a workable label — no malignancy restriction — enabling 1st-line oral positioning.
• Obefazimod captures meaningful 1st-line + 2nd-line oral share (~$3–5B+ peak UC ± CD) against clean-safety incumbents.
• Crohn’s (ENHANCE-CD) succeeds, roughly doubling the franchise.
• A premium takeout closes (~$20B+) or the independent launch executes well; dilution stays contained.
• Single falsification test: an FDA malignancy warning (boxed or otherwise) or a 2nd-line-restricted label at approval — this alone breaks the 1st-line thesis and the takeout math, and the stock at ~$11B EV is priced for the opposite.

For the bear case (current price is too high):

• The FDA imposes a malignancy warning / 2nd-line restriction, collapsing obefazimod into the JAK box; peak sales and takeout price both fall sharply.
• Obefazimod launches stuck in post-biologic 2nd-line, losing 1st-line share to clean IL-23s and TL1As, as a slower-onset oral.
• Crohn’s disappoints or slips, leaving a single restricted indication on a finite patent runway (CoM 2030).
• No premium takeout materializes; serial dilution continues; the ~$11B EV de-rates toward ~$6–9B risk-adjusted fair value (or lower in the bear label case).
• Single falsification test: a clean FDA label (no malignancy warning, 1st-line-eligible) — this validates the entire premium and turns the current price from expensive into cheap.

The symmetry is the whole point: both cases pivot on the same fact — the FDA’s malignancy adjudication — which is unknown today, unresolved by the (excellent) efficacy data, and priced by the market as if already decided favorably. That is the variant perception, and it is why the honest position is de-risked-on-efficacy, not-de-risked-on-label.

15. Source Appendix

See the Source Appendix below for the full, categorized source list with URLs and access dates. Primary sources include: Abivax 20-F (FY2025, filed 2026-03-23) and interim 6-Ks; the ABTECT induction (2025), maintenance Part 1 (2026-06-01) and Part 2 (2026-06-29) press releases; the July 2026 424B5 prospectus supplement; SEC EDGAR XBRL financial data; the 5-year price history; a public quantitative factor model; and peer-drug pivotal-trial publications (RINVOQ, Omvoh/LUCENT, Velsipity/ELEVATE, GEMINI-1, tulisokibart/ARTEMIS, duvakitug) and UC market/epidemiology sources.

This article carries no buy/sell recommendation and no price target; the single, deliberately-labeled exception is the Claude's Take block, which is the author’s own independent subjective view. General information, not investment advice.

APPENDIX A — Standard Diligence Questionnaire — Abivax SA (NASDAQ: ABVX)

Supplemental to the main analysis. Fact / Interpretation / Assumption labels applied where it matters. Where a question does not map to a pre-revenue clinical biotech, the correct sector analog is given.

General

What thoughtful questions have other investors asked about this company? The debate is unusually concentrated on one question: will the FDA restrict obefazimod’s label over the 50 mg malignancy signal? Around it orbit: (a) Is the June-2026 cancer cluster real or small-number noise (25 mg was clean; integrated rate within UC background, but 50 mg maintenance rate above it)? (b) Can a slower-onset oral win 1st-line share against clean-safety IL-23s and an incoming TL1A wave? © Does Crohn’s (ENHANCE-CD) work, and when does it read out (2H26 vs mid-27)? (d) Is a Lilly/AZ takeout real, and does it close before or after the label is known? (e) Is ~$11–12B EV pre-approval already pricing the bull case? (f) How much more dilution before self-commercialization?

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? N/A — no earnings; deeply loss-making by design (FY2025 net loss €336M). The analog is program stage: the company sits at its maximum de-risking inflection (both Phase 3 readouts positive, NDA imminent), i.e., a value high, not an earnings cycle.

Driven by external environment or internal actions? Internal — clinical trial outcomes and regulatory decisions, not macro. Return variance is >99% idiosyncratic (a factor model explains under 1% of its return variance). (FACT.)

How stable are revenues? No revenue. Future revenue (post-approval, ~2027–2028) would be a chronic, recurring specialty-pharma stream — stable if approved and adopted.

Outlook for products/services; how big is this market? Obefazimod targets moderate-to-severe UC (global UC drug market ~$8–9B → ~$16B by 2033–34) and, via ENHANCE-CD, Crohn’s (broader IBD ~$21B → ~$28B by 2030). Large, growing, high-priced, international. (FACT — GMInsights/Grand View.)

Business Quality & Competitive Moat

Is the industry getting more or less competitive? More. UC advanced therapy already holds anti-TNF, vedolizumab, three IL-23s, two JAKs, two S1Ps, with an incoming TL1A wave (tulisokibart Phase-3-positive, duvakitug). Classic Marathon “high returns attract capital” — intensifying. (INTERPRETATION.)

How profitable is the business (ROIC/ROE)? Deeply negative by construction; ROIC/ROE are not meaningful for a pre-revenue biotech. The relevant metric is probability-weighted NPV of obefazimod, not returns on today’s capital.

How profitable is the industry; barriers to entry? The end-market is highly profitable for winners (net prices ~$30–190k/year) but has low structural barriers to a new mechanism — capital and clinical know-how are abundant. Obefazimod’s barrier is patents + first-mover, not scale or captivity.

Can the business be easily understood? Yes — one oral drug, one novel mechanism (miR-124 enhancement), two IBD indications, one imminent NDA. Refreshingly simple.

Undermined by foreign low-cost labor? No. The relevant analog is generic/biosimilar competition at loss-of-exclusivity — and as an oral small molecule, obefazimod is fully generic-vulnerable once the composition-of-matter patent (2030, extendable) and method-of-use patent (2035) lapse. (FACT — 20-F.)

Do brands matter? Nature of competition? Switching costs? Brand matters modestly (GI KOL/prescriber trust); competition is on efficacy, safety label, route, and payer positioning. Patient switching costs are low-to-moderate (chronic therapy, but step-therapy and cycling between mechanisms is common) — no durable customer captivity.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The primary asset — obefazimod’s clinical value — is vastly understated on the balance sheet (carried near cost as ~€44M of intangibles/goodwill for the ABX464 CGU), while the market values the program at ~$11B. This is the definitional feature of a successful clinical biotech. (FACT/INTERPRETATION.)

Off-balance-sheet liabilities? CDMO manufacturing commitments and clinical-trial obligations exist; no unusual off-balance-sheet leverage. Venture debt/converts already extinguished.

How conservative is the accounting? Conservative — IFRS; intangibles carried at cost, not amortized, subject to impairment if the program fails. The main quality-of-earnings caveat is that IFRS net loss (€336M FY25) materially overstates cash burn (~€161M FY25 operating burn) due to non-cash SBC and convert fair-value remeasurement — use cash burn, not net loss. CIR tax credit is immaterial (~€3.1M). (FACT.)

How CapEx-hungry? Minimal physical capex (69 employees, CDMO-reliant, no owned manufacturing). The “capex” analog is R&D + a future commercial build — the real cash sink.

Capital Allocation & Management

How much FCF; how is it used; philosophy? FCF is deeply negative (~−€200M/year and rising). “Capital allocation” = timing equity raises to fund the program at minimum dilution — done well (ascending prices €6.50 → €10.99 IPO → $64 → $125, into strength). (FACT.)

Significant acquisitions recently? None — Abivax is the target, not an acquirer (Lilly/AZ rumored).

Buying back shares? No — the opposite; it is a serial issuer (~19M shares 2022 → ~86M pro-forma). Buybacks would be irrational pre-revenue.

Issuing large amounts of new shares to insiders? Insider ownership is low (~1.4%); comp is equity-linked (options/BSA/BSPCE, ~8.86M overhang → ~95M fully diluted) but not abusive. CEO cash comp ~€1.05M. (FACT.)

Compensation/motivations of management? Heavily equity-aligned to the binary outcome and share price — appropriate incentive alignment for a single-asset biotech. Management (CEO de Garidel) has signaled patience on M&A to “secure better terms,” implying a play for a higher takeout price or well-funded independence. (FACT/INTERPRETATION.)

Valuation & Market Data

ADR, MLP, or K-1 issuer? ADR — Nasdaq ADSs (1 ADS = 1 ordinary share), primary listing Euronext Paris; foreign private issuer filing 20-F/6-K. EUR functional currency; USD-denominated ADSs (FX translation noise). No MLP/K-1.

Dividend policy? None, and none expected — all capital funds R&D.

How profitable is the business? Pre-revenue; unprofitable by design.

Is net income diverging from cash from operations? Yes, materially — net loss (€336M FY25) >> operating cash burn (~€161M) due to non-cash SBC and convert remeasurement. Always reconcile to cash. (FACT.)

Risks & Downside

What would cause the stock to decline? (1) An FDA malignancy warning / restrictive label at the Q4-2026 NDA (the dominant risk); (2) a CRL / approval delay; (3) Crohn’s (ENHANCE-CD) failure; (4) competitive share loss to IL-23s/TL1As; (5) a takeout premium evaporating; (6) valuation de-rating from ~$11B EV toward ~$6–9B risk-adjusted fair value; (7) further dilution.

Risk of catastrophic loss? Real but moderated by the strength of the Phase 3 efficacy (which makes outright non-approval less likely) and the funded balance sheet (no insolvency risk through the catalyst). A malignancy-restricted label or a CRL would be a severe (not total) impairment; a Crohn’s failure plus a bad UC label is the genuine multi-leg downside.

Chance of a total loss? Low in the near term — the drug works (efficacy is proven), the balance sheet is funded into Q2 2029, and takeout interest provides a floor. Total loss would require both a failed/withdrawn NDA and no acquirer — unlikely given the data, but not impossible for a single-asset company.

Recent News & Events

Has the business environment changed recently? Dramatically. In the trailing ~2 months: positive Phase 3 maintenance Part 1 (June 1) with the malignancy signal → −44%; positive Part 2 + strengthened safety database (June 29) → +38%; and an $800M raise (July 2) into the spike, extending runway into Q2 2029. NDA on track for late Q4 2026. (FACT.)

Significant acquisitions? None by Abivax; persistent inbound takeover speculation (Lilly, AstraZeneca; deal-value chatter up to ~$23B), with the company denying AZ data-room reports and signaling patience. (FACT/INTERPRETATION.)

Change in accounting policies? None material; the notable change is the capital-structure cleanup (converts/venture debt extinguished, royalty certs repurchased) moving equity from negative to +~€430M.

Recent changes — new markets, facilities, management? Building toward U.S. commercialization (Waltham, MA office; potential salesforce build); NDA preparation; ENHANCE-CD Crohn’s Phase 2b ongoing.

APPENDIX B — Source Appendix — Abivax SA (NASDAQ: ABVX)

Primary sources prioritized over secondary. All URLs accessed 2026-07-03 unless noted. Third-party aggregated data is reconciled to primary filings; where they disagree, the filing governs.

1. Company primary filings (SEC EDGAR — CIK 0001956827)

• Form 20-F, FY2025 (filed 2026-03-23) — annual report: business, pipeline, IP/patent schedule (composition-of-matter 2030, method-of-use 2035, synthesis/polymorph 2037), risk factors, financial statements. https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm
• Form 20-F, FY2024 (filed 2025-03-24) and FY2023 (filed 2024-04-05) — prior annual reports (burn/dilution history).
• Form 6-K, 2026-06-01 — ABTECT Maintenance Part 1 topline (Wk44 clinical remission 25mg 50.8% / 50mg 51.3% vs pbo 10.4%; endoscopic/CS-free/sustained remission; safety incl. 50mg malignancies). https://www.globenewswire.com/news-release/2026/06/01/3304711/0/en/abivax-announces-landmark-phase-3-abtect-maintenance-trial-results-evaluating-obefazimod-in-moderately-to-severely-active-ulcerative-colitis.html
• Form 6-K, 2026-06-29 — ABTECT Maintenance Part 2 (non-responders 50mg 37.2% remission; relapsers 45.0%; integrated exposure 1,704 patient-years; NDA on track Q4 2026). https://www.globenewswire.com/news-release/2026/06/29/3319283/0/en/abivax-reports-positive-abtect-maintenance-part-2-results-for-obefazimod...html
• Form 424B5 (prospectus supplement, 2026-07-02) — $800M offering: 6,400,000 ADSs @ $125.00 ($762M net); pro-forma 86,094,535 shares (87,054,535 w/ option); runway “into Q2 2029”; malignancy EAIR tables (integrated 50mg 0.64, Ph3-maintenance 50mg 0.91 vs UC reference 0.30–0.70). https://www.sec.gov/Archives/edgar/data/1956827/000119312526294491/d111359d424b5.htm
• ABTECT Induction topline (Abivax IR, 2025) — both ABTECT-1/2 met Wk8 primary endpoint (50mg pooled Δ16.4pp; 25mg ABTECT-1 Δ21.4pp). https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week
• Interim 6-Ks and financial press releases (Q4’25 2026-03-23; Q1’26 2026-05-22; H1/Q reports) —

2. Financial / quantitative data (reconciled to filings)

• Company financial statements (20-F / 6-K, reconciled via public data aggregators) — income statement, balance sheet, cash flow FY2022–Q1’26 (R&D €103/146/178M; operating loss €127/173/246M; net loss €148/176/336M; cash Q1’26 €491.6M; shares 79.29M; net cash €477M).
• SEC EDGAR XBRL — CIK resolution, filing index, form breakdown.
• 5-year daily price history — split/dividend-adjusted OHLCV, EMAs, beta/alpha; 2025-07-23 → 2026-07-02 (238 bars).
• Own-history valuation percentiles — own-history percentiles (composite 99th) noted as un-interpretable for a pre-revenue biotech (near-zero revenue / negative EPS); not relied upon.
• Public quantitative factor model — Market beta ~0.60, SmallSize ~0.18, R²≈0.7% (near-zero factor explanation); beta 0.95 / alpha 1.03 realized; rs_12m +110.9. Snapshot stale (dated 2026-05-29/31, pre-June).

3. Competitive-landscape & clinical comparators (peer pivotal data)

• Upadacitinib (Rinvoq) UC — U-ACHIEVE / U-ACCOMPLISH (induction Wk8 26%/33% vs 5%/4%; maintenance Wk52 42%/52%); FDA boxed warning (malignancy/MACE/thrombosis). PMC9972647; AbbVie RINVOQ HCP pages.
• Mirikizumab (Omvoh) UC — LUCENT-1/2/3 (induction Wk12 24.2% vs 13.3%; maintenance ~50–51%). Eli Lilly FDA approval PR (2023-10).
• Etrasimod (Velsipity) UC — ELEVATE UC 52/12 (Wk12 27% vs 7%; Wk52 32% vs 7%). Lancet 2023, PIIS0140-6736(23)00061-2.
• Vedolizumab (Entyvio) UC — GEMINI-1 (Wk52 clinical remission ~42–45% vs ~16%). NEJM NEJMoa1215734.
• Tulisokibart (anti-TL1A, Merck/Prometheus) — ARTEMIS-UC Phase 2 (Wk12 26% vs 1%); NEJM NEJMoa2314076; Phase 3 ATLAS-UC positive 2026. Duvakitug (Sanofi/Teva) — RELIEVE Phase 2b (~48% vs 20%); Sanofi PR 2026-02-17.

4. Mechanism, market sizing, epidemiology

• Obefazimod / miR-124 mechanism — PMC10132720 (“ABX464 up-regulates miR-124…”, 2023); Abivax science page https://www.abivax.com/science/obefazimod ; pipeline https://www.abivax.com/pipeline/
• UC/IBD market & epidemiology — GMInsights UC market report; Grand View Research IBD; iHealthcareAnalyst; DelveInsight UC epidemiology. Advanced-UC pricing — SKYRIZI/RINVOQ cost pages; Drugs.com price guides; CDA-AMC cost tables.

5. M&A / news / market context (secondary — treat as signal, validate to primary)

• CNBC (2026-01-09; 2026-03-24; 2026-06) — takeover speculation (Lilly, AstraZeneca), ~$23B deal-value chatter, CEO “in no rush,” AZ data-room denial.
• BioPharma Dive (2026-06) — “Abivax shares surge as worries subside over immune drug’s cancer risk.”
• FierceBiotech (2026-06) — “Abivax rebounds from stock drop with safety data.”
• Euronext Paris (ABVX.PA) long-run price context — Yahoo Finance / MarketScreener (52-wk €6.55–132.00; ATL €3.85 2016; listed 2015; Nasdaq listed 2023-10-20).